Pulse Biosciences Announces Appointment of David Kenigsberg, M.D. as Chief Medical Officer of Electrophysiology
Pulse Biosciences (PLSE) has appointed Dr. David Kenigsberg as Chief Medical Officer of Electrophysiology and added Dr. Andrea Natale as a medical advisor. Dr. Kenigsberg, founder of Florida Heart Rhythm Specialists, joins to support the development of the company's nano-PFA 360 Cardiac Catheter. Dr. Natale, Executive Medical Director of Texas Cardiac Arrhythmia Institute, will join existing advisors Dr. Vivek Reddy and Dr. Jacob Koruth to advance the clinical development of the catheter technology for treating atrial fibrillation.
Pulse Biosciences (PLSE) ha nominato il Dr. David Kenigsberg come Chief Medical Officer per l'elettrofisiologia e ha aggiunto il Dr. Andrea Natale come consulente medico. Il Dr. Kenigsberg, fondatore di Florida Heart Rhythm Specialists, si unisce per supportare lo sviluppo del catetere cardiaco nano-PFA 360 dell'azienda. Il Dr. Natale, Direttore Medico Esecutivo del Texas Cardiac Arrhythmia Institute, si unirà agli attuali consulenti Dr. Vivek Reddy e Dr. Jacob Koruth per promuovere lo sviluppo clinico della tecnologia del catetere per il trattamento della fibrillazione atriale.
Pulse Biosciences (PLSE) ha nombrado al Dr. David Kenigsberg como Director Médico de Electrofisiología y ha añadido al Dr. Andrea Natale como asesor médico. El Dr. Kenigsberg, fundador de Florida Heart Rhythm Specialists, se une para apoyar el desarrollo del catéter cardíaco nano-PFA 360 de la compañía. El Dr. Natale, Director Médico Ejecutivo del Texas Cardiac Arrhythmia Institute, se unirá a los asesores existentes Dr. Vivek Reddy y Dr. Jacob Koruth para avanzar en el desarrollo clínico de la tecnología del catéter para el tratamiento de la fibrilación auricular.
Pulse Biosciences (PLSE)는 David Kenigsberg 박사를 전기생리학 최고 의학 책임자로 임명하고, Andrea Natale 박사를 의료 자문으로 추가했습니다. Florida Heart Rhythm Specialists의 창립자인 Kenigsberg 박사는 회사의 nano-PFA 360 심장 카테터 개발을 지원하기 위해 합류했습니다. Texas Cardiac Arrhythmia Institute의 전무 의학 이사인 Natale 박사는 기존 자문인 Vivek Reddy 박사 및 Jacob Koruth 박사와 함께 심방세동 치료를 위한 카테터 기술의 임상 개발을 진전시키기 위해 합류할 것입니다.
Pulse Biosciences (PLSE) a nommé le Dr. David Kenigsberg au poste de directeur médical en électrophysiologie et a ajouté le Dr. Andrea Natale en tant que conseiller médical. Le Dr. Kenigsberg, fondateur de Florida Heart Rhythm Specialists, rejoint l'entreprise pour soutenir le développement du cathéter cardiaque nano-PFA 360. Le Dr. Natale, directeur médical exécutif de l'Institut Texas Cardiac Arrhythmia, rejoindra les conseillers existants, le Dr. Vivek Reddy et le Dr. Jacob Koruth, pour faire progresser le développement clinique de la technologie de cathéter pour le traitement de la fibrillation atriale.
Pulse Biosciences (PLSE) hat Dr. David Kenigsberg zum Chief Medical Officer für Elektrophysiologie ernannt und Dr. Andrea Natale als medizinischen Berater hinzugefügt. Dr. Kenigsberg, Gründer der Florida Heart Rhythm Specialists, wird unterstützt, um die Entwicklung des nano-PFA 360 Herzkatheters des Unternehmens voranzutreiben. Dr. Natale, Medizinischer Geschäftsführer des Texas Cardiac Arrhythmia Institute, wird sich den bestehenden Beratern Dr. Vivek Reddy und Dr. Jacob Koruth anschließen, um die klinische Entwicklung der Kathetertechnologie zur Behandlung von Vorhofflimmern zu fördern.
- Strengthened medical leadership with appointment of experienced cardiac electrophysiologist as CMO
- Added prominent medical advisor expanding clinical expertise team
- Advancing development of innovative nano-PFA 360 Cardiac Catheter technology
- None.
Adds Andrea Natale, M.D. as a medical advisor, joining existing advisors Vivek Reddy, M.D. and Jacob Koruth, M.D.
“I am inspired by the potential of nano-PFA and the unique catheter design of the 360 catheter that is already demonstrating the ability to isolate pulmonary veins with ease and speed,” said Dr. David Kenigsberg, Chief Medical Officer of Electrophysiology of Pulse Biosciences. “I was impressed when I saw the 360 catheter in use and am excited to work with Pulse to deliver robust clinical data with the 360, which I believe will substantially advance the treatment of atrial fibrillation. I look forward to supporting this team through its next phase of clinical development.”
Dr. Kenigsberg is a practicing cardiac electrophysiologist with a passion for treating atrial fibrillation over his career. He is the founder of Florida Heart Rhythm Specialists and Ft. Lauderdale Heart & Rhythm Surgical Center. He has been the Medical Director of the Electrophysiology Lab at HCA Westside Medical Center in
“This is an exciting time in electrophysiology as pulsed field ablation technologies are becoming widely adopted and advancing the standard of care. I am excited to support the Pulse team in the clinical efforts for the 360 catheter,” added Dr. Andrea Natale.
Dr. Andrea Natale is the Executive Medical Director of the Texas Cardiac Arrhythmia Institute at St. David’s Medical Center in
Burke T. Barrett, President and Chief Executive Officer of Pulse Biosciences concluded, “We are significantly strengthening our team with the addition of these renowned physicians who will contribute to generating high quality clinical data that demonstrates the clinical performance profile of the 360 catheter. I want to thank Drs. Reddy and Koruth for their significant contributions in the pre-clinical and clinical evaluations of the 360 catheter to date.”
About Pulse Biosciences®
Pulse Biosciences is a novel bioelectric medicine company committed to health innovation that has the potential to improve the quality of life for patients. The Company’s proprietary CellFX® nsPFA™ technology delivers nanosecond pulses of electrical energy to non-thermally clear cells while sparing adjacent noncellular tissue. The Company is actively pursuing the development of its CellFX nsPFA technology for use in the treatment of atrial fibrillation and in a select few other markets where it could have a profound positive impact on healthcare for both patients and providers. Pulse Biosciences is now headquartered in
Pulse Biosciences, CellFX, Nano-Pulse Stimulation, NPS, nsPFA, CellFX nsPFA and the stylized logos are among the trademarks and/or registered trademarks of Pulse Biosciences, Inc. in
View source version on businesswire.com: https://www.businesswire.com/news/home/20241030976724/en/
Investors:
Pulse Biosciences, Inc.
Burke T. Barrett, President and CEO
IR@pulsebiosciences.com
Or
Gilmartin Group
Philip Trip Taylor
415.937.5406
philip@gilmartinir.com
Source: Pulse Biosciences, Inc.
FAQ
Who is the new Chief Medical Officer of Electrophysiology at Pulse Biosciences (PLSE)?
What is the main product Pulse Biosciences (PLSE) is developing?
Who are the medical advisors for Pulse Biosciences (PLSE)?
